Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.

Paul K KeithJuthaporn CowanAmin KananiHarold KimGina LacuestaJason K LeeJie ChenMichelle ParkAndré Gladiator

Published in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2022)

This study provides a detailed description of Ig20Gly infusion parameters, tolerability, and quality of life in clinical practice among patients with PID or SID switching to Ig20Gly from another SCIG and confirms the feasibility of infusing Ig20Gly via pump or manual administration. Trial registration NCT03716700, Registered 31 August 2018, https://clinicaltrials.gov/ct2/show/NCT03716700.

Keyphrases

clinical practice
clinical trial
computed tomography
magnetic resonance imaging
open label
image quality
double blind